Related Experiment Videos
Genetically modified tumour vaccines--where we are today
1Department of Cancer Immunology, University School of Medical Sciences, GreatPoland Cancer Centre, Poznań, Poland.
Cancer Treatment Reviews
|April 23, 1999
Summary
Tumour vaccines aim to boost anti-cancer immune responses. Newer generations, using genetically modified cells or antigens, show promise for treating resistant cancers like melanoma with minimal toxicity.
Area of Science:
- Immunology
- Oncology
- Vaccinology
Background:
- Tumour vaccines stimulate anti-cancer immunity against residual or metastatic cells.
- Cellular cytotoxicity, requiring specific antigen presentation, costimulatory, and propagation signals, is crucial for tumour elimination.
Purpose of the Study:
- To review the development and efficacy of tumour vaccines.
- To highlight advancements in tumour vaccine technology and their clinical potential.
Main Methods:
- Characterization of HLA-restricted tumour antigens recognized by cytotoxic T-cells.
- Development of first-generation vaccines using whole tumour cells or lysates with non-specific adjuvants.
- Creation of second-generation vaccines involving genetically modified tumour cells, dendritic cells, or recombinant tumour antigens.
Main Results:
- First-generation vaccines yielded approximately 20% clinical response rates.
- Second-generation vaccines, engineered to provide necessary signals for T-cell activation, demonstrate specific immune responses and objective clinical responses with minimal toxicity in early trials.
Conclusions:
- Advances in gene transfer and tumour immunology support the clinical introduction of tumour vaccines.
- Tumour vaccines offer hope for treating malignancies resistant to current therapies, such as melanoma and renal cell carcinoma.